Exome Sequencing IDs Plavix Response Variants that Could Lead to Better PGx Test | GenomeWeb

By Monica Heger

Despite being
the third best-selling drug in 2010, as many as one-third of cardiology patients do not respond to Bristol-Myers Squibb's blood-thinning drug Plavix (clopidogrel).

While recent studies have uncovered one genetic variant highly predictive of response — the CYP2C19*2 allele, it doesn't explain all non-responders.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.